asxan.ai Agents Hub

Soy Isoflavones

Evidence Fact Sheet

Genistein · Daidzein · Glycitein

Soy isoflavones (genistein, daidzein, glycitein) are plant phytoestrogens with preferential ER-beta binding, studied for bone, vasomotor, lipid and blood-pressure outcomes. Meta-analyses show modest spine BMD, hot-flash and LDL effects; blood-pressure benefit is significant only in hypertensive subgroups. Sold as a supplement; EFSA has authorized 0 health claims.

Also known as: Soy Isoflavones · Genistein · Daidzein · Glycitein · Soy phytoestrogens

Overview

Soy isoflavones are a class of plant-derived phytoestrogens — chiefly genistein, daidzein and glycitein — that bind estrogen receptors with preferential ER-beta affinity, giving them SERM-like behavior in research contexts; their bioactivity varies with gut-microbiome equol-producer status (roughly half to two-thirds of people are non-equol-producers). They are also studied as antioxidant/anti-inflammatory and bone-metabolism modulators. Human trials and commercial products typically use 40-100 mg/day of isoflavone aglycone-equivalents (EFSA's 2015 safety review found no adverse breast/thyroid/uterine effect in postmenopausal women at or below 100 mg/day). Regulatory status: a legal dietary-supplement ingredient in the US under DSHEA, marketable as a food supplement in the EU and Brazil; China authorizes a single health-food function (increasing bone density), while EFSA has authorized zero health claims. This is an educational evidence summary, not a dosing or treatment recommendation.

Mechanism of Action

Selective estrogen-receptor modulation (phytoestrogen · preferential ER-beta binding · SERM-like research context) · Equol metabolism: ~50-70% of consumers are non-equol-producers, affecting bioactivity (gut-microbiome dependent) · Antioxidant / anti-inflammatory effects (research-stage biomarkers) · Bone metabolism modulation: influence on osteoblast/osteoclast balance (research context, basis of CN bone-density function)

Body systems: HORMONE · Musculoskeletal · Cardiovascular

Evidence-Based Benefits

Each benefit below is anchored to a specific PubMed-indexed study. Effect sizes, sample sizes, and p-values are reported as published; no values are inferred. Honest negatives and null results are kept alongside the positive findings, and disease-research populations are described as such — Soy Isoflavones is not characterized as a treatment for any disease.

Bone Mineral Density (Spine)

Meta-analysis supported
  • 20.6 mg/cm2spine BMD vs control
  • 28.5 mg/cm2>90 mg/day subgroup

A meta-analysis of randomized trials in menopausal women found that isoflavone intake significantly increased spine bone mineral density versus control, with a larger effect at doses above 90 mg/day. This is consistent with China's single authorized health-food function (increasing bone density); it is a research finding on a bone biomarker, not osteoporosis treatment.

Reported effect: Spine BMD increased significantly by 20.6 mg/cm2 (95% CI: 4.5-36.6); with intake >90 mg/day the increase was 28.5 mg/cm2 (95% CI: 8.4-48.6).

“The spine bone mineral density in subjects who consumed isoflavones increased significantly by 20.6 mg/cm(2) (95% confidence interval: 4.5-36.6 mg/cm(2)) in comparison to that in subjects who did not consume isoflavones. ... Increases in the spine bone mineral density with isoflavone intake of more than 90 mg/day and with treatment lasting 6 months were 28.5mg/cm(2) (95% confidence interval: 8.4-48.6 mg/cm(2)) and 27 mg/cm(2) (95% confidence interval: 8.3-45.8 mg/cm(2)), respectively.”

Source: PMID 18063230 · Ma 2008 · Clin Nutr

Menopausal Hot Flashes (Vasomotor)

Meta-analysis supported
  • -20.6%frequency · P<0.00001
  • -26.2%severity · P=0.001

A systematic review and meta-analysis found that extracted or synthesized soy isoflavones significantly reduced both the frequency and severity of hot flashes versus placebo in peri- and postmenopausal women. This is a research finding; product content must not claim to treat menopause syndrome.

Reported effect: Hot-flash frequency reduced by 20.6% (95% CI -28.38 to -12.86; P<0.00001) and severity by 26.2% (95% CI -42.23 to -10.15; P=0.001) vs placebo (median 54 mg aglycone equivalents).

“Meta-analysis revealed that ingestion of soy isoflavones (median, 54 mg; aglycone equivalents) for 6 weeks to 12 months significantly reduced the frequency...of hot flashes by 20.6% (95% CI, -28.38 to -12.86; P < 0.00001) compared with placebo ... isoflavones significantly reduced hot flash severity by 26.2% (95% CI: -42.23 to -10.15, P = 0.001) compared with placebo”

Source: PMID 22433977 · Taku 2012 · Menopause

LDL & Total Cholesterol

Meta-analysis supported
  • -0.13 mmol/LLDL · P<0.0001
  • -0.10 mmol/Ltotal chol · P=0.02

A meta-analysis of 11 RCTs found soy isoflavones produced small but statistically significant reductions in serum total and LDL cholesterol, with no significant change in HDL or triglycerides. The magnitude is modest; note EFSA rejected an LDL-cholesterol health claim for isoflavones.

Reported effect: Total cholesterol -0.10 mmol/L (3.9 mg/dL or 1.77%; P=0.02) and LDL cholesterol -0.13 mmol/L (5.0 mg/dL or 3.58%; P<0.0001); no significant change in HDL or triacylglycerol.

“Soy isoflavones significantly decreased serum total cholesterol by 0.10 mmol/L (3.9 mg/dL or 1.77%; P = 0.02) and LDL cholesterol by 0.13 mmol/L (5.0 mg/dL or 3.58%; P < 0.0001) ... no significant changes in HDL cholesterol and triacylglycerol were found”

Source: PMID 17413118 · Taku 2007 · Am J Clin Nutr

Blood Pressure (Overall Null; Effect in Hypertensives)

Null / no benefit Meta-analysis supported
  • -2.5 mm Hgsystolic overall · P=0.08
  • -5.94 mm Hgsystolic · hypertensive subgroup
  • 0.29 mm Hgsystolic · normotensive · P=0.83

Honest negative: across all trials, soy isoflavones did NOT significantly lower systolic or diastolic blood pressure (both P=0.08). A significant reduction appeared only in the hypertensive subgroup, while normotensive subjects showed no effect. Any BP framing should be limited to this subgroup nuance.

Reported effect: Overall SBP -2.5 mm Hg (95% CI -5.35 to 0.34; P=0.08) and DBP -1.5 mm Hg (95% CI -3.09 to 0.17; P=0.08), both non-significant; hypertensive subgroup SBP -5.94 mm Hg (95% CI -10.55 to -1.34; P=0.01); normotensive SBP 0.29 mm Hg (95% CI -2.39 to 2.97; P=0.83).

“Meta-analysis results showed a mean decrease of 2.5 mm Hg (95% CIs, - 5.35 to 0.34 mm Hg; P = 0.08) for systolic blood pressure and 1.5 mm Hg (95% CIs, - 3.09 to 0.17 mm Hg; P = 0.08) for diastolic blood pressure ... Subgroup analysis of hypertensive subjects revealed that a greater blood pressure reduction was identified in the soy isoflavone-treated group compared to placebo (5 trials; SBP: - 5.94, 95% CIs [- 10.55, - 1.34] mm Hg, P = 0.01; DBP: - 3.35, 95% CIs [- 6.52, - 0.19] mm Hg, P = 0.04) ... treatment with soy isoflavones did not lead to a significant reduction in blood pressure in normotensive subjects (6 trials; SBP: 0.29, 95% CIs [- 2.39, 2.97] mm Hg, P = 0.83; DBP: - 0.43, 95% CIs [- 1.66, 0.81] mm Hg, P = 0.50)”

Source: PMID 21310599 · Liu XX 2012 · Nutr Metab Cardiovasc Dis

Dosage (research context · not a recommendation)

RCT/commercial doses 40-100 mg/day isoflavone aglycone-equivalent (DSLD median ~80 mg, range 40-750 mg). EFSA 2015 safety review: postmenopausal women <=100 mg/day isoflavone aglycone-equivalent shows no adverse effect on breast, thyroid, uterus. Educational reference, not a dosing recommendation.

Regulatory Status · 4 Markets

US · FDA
Legal dietary-supplement ingredient sold freely under DSHEA (structure/function claims with disclaimer). GRN 1 (1998) was a ceased/withdrawn notification — NOT a valid GRAS. The 1999 soy-protein cardiovascular qualified health claim (25 g/day) is for soy protein, not isolated isoflavones, and FDA proposed to revoke it in 2017 (not finalized). No FDA-authorized health claim for soy isoflavones.
EU · EFSA
Marketable as food supplement under Directive 2002/46/EC. EFSA has authorized 0 health claims — 6 Art.13(1) applications (incl. hair growth EFSA 2011;9(7):2264, LDL cholesterol, joint maintenance EFSA 2010;8(2):1493) were all rejected. EFSA 2015 safety review confirmed postmenopausal use <=100 mg/day aglycone-equivalent has no adverse effect on breast/thyroid/uterus.
CN · China
China SAMR: listed in health-food raw-material catalogue; authorized health-food function limited to increasing bone density. Other directions (menopause/skin/cardiovascular) not permitted on labels.
BR · ANVISA
Legal food-supplement ingredient under ANVISA RDC 243/2018 + IN 28/2018; any claim must conform to the ANVISA positive list. No specific IN 28/2018 Anexo V authorized functional claim asserted for soy isoflavones.

Safety

Soy allergy = absolute contraindication; all packaging/content must carry allergen warning. Equol non-producer variability (~50-70%) means responses differ — avoid over-promising. Must NOT claim it treats menopause syndrome, prevents breast cancer, or replaces hormone-replacement therapy; must NOT be recommended in content aimed at breast-cancer patients. High-dose genistein may affect TPO activity in iodine-deficient individuals (thyroid caution). This describes scientific evidence, not medical advice.

Goals: menopause-support · heart-health · joint-bone

Lifestyles: menopause · plant-based

References

PubMed-indexed citations anchoring the benefit findings above. Effect sizes are reported as published.

  1. PMID 18063230 · Ma 2008 · Clin Nutr — Bone Mineral Density (Spine)
  2. PMID 22433977 · Taku 2012 · Menopause — Menopausal Hot Flashes (Vasomotor)
  3. PMID 17413118 · Taku 2007 · Am J Clin Nutr — LDL & Total Cholesterol
  4. PMID 21310599 · Liu XX 2012 · Nutr Metab Cardiovasc Dis — Blood Pressure (Overall Null; Effect in Hypertensives)

Frequently Asked Questions

1. What are soy isoflavones and how do they work?

Soy isoflavones are plant phytoestrogens — mainly genistein, daidzein and glycitein — that bind estrogen receptors with preferential ER-beta affinity, giving SERM-like behavior in research contexts. Their activity also depends on gut-microbiome equol-producer status, which is why responses differ between individuals. They are studied for bone, vasomotor, lipid and blood-pressure outcomes.

2. Do soy isoflavones help with menopausal hot flashes and bone density?

Meta-analyses report measurable effects in studied populations. For hot flashes, Taku 2012 (Menopause) found frequency reduced by 20.6% and severity by 26.2% versus placebo. For bone, Ma 2008 (Clin Nutr) found spine BMD increased by 20.6 mg/cm2 versus control, with a larger 28.5 mg/cm2 effect above 90 mg/day. These are research findings, not treatments for menopause syndrome or osteoporosis.

3. Do soy isoflavones lower cholesterol or blood pressure?

For lipids, Taku 2007 (Am J Clin Nutr, 11 RCTs) found small but significant reductions: total cholesterol -0.10 mmol/L and LDL -0.13 mmol/L, with no change in HDL or triglycerides. For blood pressure, the evidence is mixed: Liu 2012 found NO significant overall effect (systolic -2.5 mm Hg, P=0.08), with a significant reduction only in the hypertensive subgroup and none in normotensive subjects.

4. What dose is used in research and what is the regulatory status?

Human trials and commercial products typically use 40-100 mg/day of isoflavone aglycone-equivalents; EFSA's 2015 safety review found no adverse breast/thyroid/uterine effect in postmenopausal women at or below 100 mg/day. Regulatorily, isoflavones are a legal supplement ingredient in the US, EU and Brazil; China authorizes only a bone-density health-food function, and EFSA has authorized zero health claims. Soy allergy is an absolute contraindication. This is educational information, not dosing or medical advice.

Last evidence review: 2026-06-22

← Evidence library

Ask Agent Axor